JARDIANCE Drug Patent Profile

When do Jardiance patents expire, and what generic alternatives are available?

Jardiance is a drug marketed by Boehringer Ingelheim and is included in one NDA. There are fifteen patents protecting this drug and one Paragraph IV challenge.

This drug has four hundred and thirty-six patent family members in forty-six countries.

The generic ingredient in JARDIANCE is empagliflozin. There are twenty-two drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the empagliflozin profile page.

DrugPatentWatch^® Generic Entry Outlook for Jardiance

Jardiance was eligible for patent challenges on August 1, 2018.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be February 1, 2029. This may change due to patent challenges or generic licensing.

Annual sales in 2022 were $13.0bn, indicating a strong incentive for generic entry.

There have been fifty-one patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

There are nineteen tentative approvals for the generic drug (empagliflozin), which indicates the potential for near-term generic launch.

Indicators of Generic Entry

Summary for JARDIANCE

International Patents:	436
US Patents:	15
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	4
Raw Ingredient (Bulk) Api Vendors:	81
Clinical Trials:	82
Patent Applications:	1,881
Drug Prices:	Drug price information for JARDIANCE
Drug Sales Revenues:	Drug sales revenues for JARDIANCE
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for JARDIANCE
What excipients (inactive ingredients) are in JARDIANCE?	JARDIANCE excipients list
DailyMed Link:	JARDIANCE at DailyMed

See drug prices for JARDIANCE

See drug sales revenues for JARDIANCE

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for JARDIANCE

NDA:

204629

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for JARDIANCE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Boehringer Ingelheim	PHASE1
Odense University Hospital	PHASE4
The Pittsburgh Foundation	PHASE4

See all JARDIANCE clinical trials

Pharmacology for JARDIANCE

Drug Class	Sodium-Glucose Cotransporter 2 Inhibitor
Mechanism of Action	Sodium-Glucose Transporter 2 Inhibitors

Paragraph IV (Patent) Challenges for JARDIANCE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
JARDIANCE	Tablets	empagliflozin	10 mg and 25 mg	204629	14	2018-08-01

US Patents and Regulatory Information for JARDIANCE

JARDIANCE is protected by fifteen US patents and three FDA Regulatory Exclusivities.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Boehringer Ingelheim	JARDIANCE	empagliflozin	TABLET;ORAL	204629-002	Aug 1, 2014		RX	Yes	Yes
Boehringer Ingelheim	JARDIANCE	empagliflozin	TABLET;ORAL	204629-002	Aug 1, 2014		RX	Yes	Yes					Y
Boehringer Ingelheim	JARDIANCE	empagliflozin	TABLET;ORAL	204629-002	Aug 1, 2014		RX	Yes	Yes
Boehringer Ingelheim	JARDIANCE	empagliflozin	TABLET;ORAL	204629-002	Aug 1, 2014		RX	Yes	Yes					Y
Boehringer Ingelheim	JARDIANCE	empagliflozin	TABLET;ORAL	204629-001	Aug 1, 2014		RX	Yes	No
Boehringer Ingelheim	JARDIANCE	empagliflozin	TABLET;ORAL	204629-001	Aug 1, 2014		RX	Yes	No
Boehringer Ingelheim	JARDIANCE	empagliflozin	TABLET;ORAL	204629-002	Aug 1, 2014		RX	Yes	Yes					Y

EU/EMA Drug Approvals for JARDIANCE

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Boehringer Ingelheim International GmbH	Jardiance	empagliflozin	EMEA/H/C/002677Type 2 diabetes mellitusJardiance is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exerciseas monotherapy when metformin is considered in addition to other medicinal products for the treatment of diabetesFor study results with respect to combinations of therapies, effects on glycaemic control, and cardiovascular and renal events, and the populations studied, see sections 4.4, 4.5 and 5.1. of the annex.Heart failureJardiance is indicated in adults for the treatment of symptomatic chronic heart failure. Chronic kidney diseaseJardiance is indicated in adults for the treatment of chronic kidney disease.	Authorised	no	no	no	2014-05-22

International Patents for JARDIANCE

See the table below for patents covering JARDIANCE around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	2014247092
Canada	2812519
Canada	2908635
Canada	3121761
Chile	2015002940
China	105377267
China	109893534

Supplementary Protection Certificates for JARDIANCE

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1730131	62/2014	Austria		PRODUCT NAME: (1S)-1,5-ANHYDRO-1-C-(4-CHLORO-3-((4-(((3S)-OXOLAN-3-YL)OXY(PHENYL)METHYL)PHENYL)-D-GLUCITOL (EMPAGLIFLOZIN); REGISTRATION NO/DATE: EU/1/14/930 (MITTEILUNG) 20140527
1730131	C300696	Netherlands		PRODUCT NAME: EMPAGLIFLOZINE EN ZOUTEN DAARVAN, IN HET BIJZONDER EMPAGLIFLOZINE; REGISTRATION NO/DATE: EU/1/14/930/001-009 20140522
1730131	PA2014035	Lithuania		PRODUCT NAME: EMPAGLIFLOZINUM; REGISTRATION NO/DATE: EU/1/14/930 20140522
1730131	92555	Luxembourg		PRODUCT NAME: EMPAGLIFLOZINE ET SES SELS,EN PARTICULIER EMPAGLIFLOZINE-L INGREDIENT ACTIF APPROUVE EST L EMPAGLIFLOZINE DE FORMULE(1S)-1,5-ANHYDRO-1-C-4-CHLORO-3-(4-(3S)OXOLAN-3-YLOXY PHENYL)METHYLPHENYL-D-GLUCITOL
1730131	CA 2014 00054	Denmark		PRODUCT NAME: EMPAGLIFLOZIN OG SALTE DERAF, SAERLIGT EMPAGLIFLOZIN; REG. NO/DATE: EU1/14/930/001/018 20140522
1730131	1490061-7	Sweden		PERIOD OF VALIDITY (FROM - UNTIL): 20250312 - 20290526
1730131	14C0074	France		PRODUCT NAME: EMPAGLIFLOZINE ET SES SELS, EN PARTICULIER L'EMPAGLIFLOZINE; REGISTRATION NO/DATE: EU/1/14/930 20140527

JARDIANCE Market Dynamics and Financial Trajectory (Empagliflozin)

Last updated: July 20, 2026

Executive summary: JARDIANCE (empagliflozin) has moved from early rapid uptake to sustained scale driven by type 2 diabetes (T2D) expansion and, more importantly, cardiovascular and renal outcome indications. In the US, revenue is shaped by (1) ongoing class competition from other SGLT2 inhibitors, (2) payer positioning around cardiovascular/renal benefit evidence, (3) manufacturing and supply execution, and (4) exclusivity/patent timelines that influence generic and “authorized” price competition risk. Trajectory remains closely linked to how quickly clinicians convert eligible T2D patients into cardiovascular/CKD-eligible populations and how payers operationalize those label positions.

---

How much revenue does JARDIANCE generate and what is its sales trajectory by year?

Featured snippet answer: JARDIANCE remains a top-selling branded therapy in its class, with revenue historically rising through label expansion and outcome-driven adoption, then flattening or growing at a slower pace once utilization matured and competitive dynamics intensified across SGLT2.

Commercial trajectory drivers

1. Indication expansion and evidence durability
   Empagliflozin’s commercial lift is tied to the addition and adoption of cardiovascular and renal endpoints, which increase eligible patient pools versus glucose-only indications.
2. Payer and formulary access
   Plan placement typically follows clinical guidelines and real-world prescribing patterns after outcome trials established benefit profiles.
3. Class saturation and competitor pressure
   As formularies increasingly prefer “preferred SGLT2” tiers, incremental share gains depend on conversion from competing SGLT2 inhibitors, not only new-to-class starts.
4. Geographic mix and healthcare system reimbursement
   Adoption cadence differs across the US, EU, Japan, and China, affecting revenue seasonality and growth rates.

Key financial mapping used in investment and licensing

• Sales growth vs. Net price realization: branded uptake can mask price pressure from rebates and plan negotiations.
• Market share vs. total SGLT2 growth: high brand share can still produce modest growth if class volumes are constrained.
• Indication-specific retention: patients remain on therapy if outcomes justify continuation and if renal function eligibility persists.

Source note: Detailed annual revenue numbers were not provided in the prompt; this section summarizes the market mechanics that determine the trajectory rather than quoting figures.

---

What market dynamics shape JARDIANCE performance in the SGLT2 inhibitor class?

Featured snippet answer: SGLT2 inhibitor class dynamics are dominated by payer tiering, guideline-based prescribing for cardiovascular and CKD benefit, and competitive product differentiation through trial outcomes and local access strategies.

How do payers decide between JARDIANCE, FARXIGA, and other SGLT2 competitors?

Payers commonly evaluate:

• Clinical evidence fit for enrolled populations (heart failure, CKD, ASCVD risk)
• Safety/tolerability profiles that affect adherence (genital infections, volume depletion, rare ketoacidosis risk)
• Formulary strategy (preferred brand vs. second tier vs. PA/step therapy)
• Real-world claims data that show switching behavior among SGLT2 drugs

What does guideline adoption do to demand?

• US and international cardiometabolic guidelines increasingly treat SGLT2 inhibitors as foundational for cardiorenal risk in appropriate patients.
• That shifts prescriber behavior from “T2D management” to “risk reduction,” increasing the addressable population for empagliflozin.

What competitive vectors matter most for JARDIANCE share?

1. Switching from competitor SGLT2s (especially in heart failure and CKD subsets)
2. Combination therapy patterns with GLP-1 RAs and metformin backbones
3. Contracting leverage where plans negotiate based on class revenue pools

---

Which indications drive JARDIANCE demand: T2D vs cardiovascular vs renal?

Featured snippet answer: The marginal growth that extends beyond pure glucose management usually comes from cardiovascular and renal outcomes claims, which expand eligible patient pools and support stronger payer coverage.

T2D: why it matters, but why growth can saturate

• Broad T2D eligibility generates base demand.
• Once first-line or add-on preferences stabilize, incremental starts depend on:
  • GLP-1 RA substitution dynamics
  • intolerance profiles
  • combination uptake

Cardiovascular: what determines conversion

• Adoption depends on:
  • how quickly cardiology and primary care integrate SGLT2 into heart failure pathways
  • label alignment for HF subtypes and risk stages
  • payer interpretation of eligible criteria

Renal: how CKD eligibility changes the economics

• CKD indication adoption tends to increase persistence because the benefit narrative supports longer treatment duration.
• The market responds strongly when renal function thresholds align with common real-world staging patterns.

---

What is JARDIANCE’s pricing and contracting environment (rebates, tendering, and net price)?

Featured snippet answer: Net price is shaped more by payer contracting and rebate structures than by list price, and SGLT2 market access typically drives significant variability by plan.

Common net-price mechanisms

• Formulary placement deals that trade volume for rebate
• Step therapy requirements that restrict utilization until prior glucose or other therapy history is documented
• Preferred tier switching: plans may prefer one SGLT2 based on contract economics, causing share volatility

How competitive tendering changes forecast quality

• In large US payer systems, tender decisions can reallocate share quickly across SGLT2 brands.
• Forecasting must incorporate:
  • plan-by-plan formulary update cadence
  • state Medicaid behavior
  • Medicare Part D redesign in relevant years

---

How does JARDIANCE supply and manufacturing capacity affect market share and revenue?

Featured snippet answer: Supply continuity is a baseline requirement in SGLT2 categories because prescribers and payers tie access to reliable fulfillment, and substitution increases when shortages occur.

Operational risks that hit revenue

• Manufacturing disruptions that force temporary allocation
• Raw material constraints
• Quality events that change distribution priorities

Why timing matters

• SGLT2 adherence depends on consistent dosing availability.
• Shortfalls can translate into lasting share loss if pharmacies substitute persistently.

---

What generic or biosimilar risk exists for JARDIANCE and when does exclusivity expire?

Featured snippet answer: The dominant commercial risk for JARDIANCE is not biosimilars but generic entry under Hatch-Waxman, driven by patent expiration and any Paragraph IV challenges to Orange Book-listed patents.

The prompt did not include Orange Book listings or specific patent numbers tied to empagliflozin in the requested geography. Without those items, the article cannot provide accurate expiration dates or launch scenarios.

---

What patents protect JARDIANCE and how does the patent estate influence generics entry risk?

Featured snippet answer: JARDIANCE’s patent estate typically includes compositions, formulations, and method-of-use protections, which can delay generic approval and market entry and increase settlement leverage.

The prompt did not include patent numbers, assignees, or jurisdictional scope, so this section cannot provide a complete, accurate patent-by-patent protection and litigation map.

---

What patent litigation or Paragraph IV challenges affect JARDIANCE commercialization?

Featured snippet answer: Paragraph IV litigation affects timelines through court-triggered approval stays and can shape settlement terms that determine whether generics launch at risk, enter with date-certain covenants, or remain in pending litigation.

No specific litigation records were supplied in the prompt, so this section cannot name cases, filers, case numbers, or stay/settlement dates.

---

What is the FDA regulatory status of JARDIANCE and how does it affect commercial timing?

Featured snippet answer: FDA approval status influences availability of generics via the Orange Book and determines which pathways can pursue follow-on versions while staying clear of unexpired protections.

The prompt did not include FDA approval history (NDA/BLA identifiers, supplement pathways, Orange Book patent lists), so this section cannot provide an accurate regulatory timeline.

---

How does JARDIANCE compare with FARXIGA, INVOKANA, and other SGLT2 inhibitors on market positioning?

Featured snippet answer: The class competes across overlapping cardiometabolic and cardiorenal indications. Differentiation tends to come from payer trust in evidence interpretation, local formulary contracts, switching inertia, and prescriber familiarity.

Competitive positioning framework

• Evidence breadth: how widely cardiology and nephrology teams apply trial readouts
• Payer preference: which brand is “preferred” in common formularies
• Switching thresholds: whether plans drive step therapy or require trial of another SGLT2
• Combination ecosystem: ease of co-prescribing with GLP-1 RAs and other diabetes therapies

Market share reality

• In matured SGLT2 markets, share gains frequently come from switching rather than net-new class starts.
• That elevates the importance of contracting and patient-level outcomes narratives rather than just launch mechanics.

---

What revenue exposure does JARDIANCE face from competitive substitution and price erosion?

Featured snippet answer: Revenue exposure rises when a competitor becomes preferred on major formularies or when steered utilization reduces JARDIANCE’s share within a stable class volume.

Main exposure channels

1. Formulary tier downgrade after contract renegotiations
2. Increased prior authorization burden reducing fills or slowing starts
3. Increased switching incentives through copay assistance program strategy changes
4. Price erosion as multiple brands compete for limited “preferred” slots

---

Key Takeaways

• JARDIANCE’s financial trajectory is primarily driven by indication-based expansion into cardiovascular and renal populations, then moderated by SGLT2 class saturation and payer contracting.
• Net price realization and formulary placement are the most sensitive levers behind quarter-to-quarter revenue performance in matured SGLT2 categories.
• Generic entry risk is Hatch-Waxman, not biosimilar, but a precise exclusivity expiration and launch-risk timeline requires Orange Book patent and litigation specifics, which were not provided in the prompt.

---

FAQs

1. How do SGLT2 formulary tiers typically change after cardiology guideline updates?
2. What patient segments switch most from one SGLT2 brand to another in claims data?
3. How does CKD staging distribution affect SGLT2 renal indication uptake?
4. What role do copay assistance programs play in SGLT2 net sales and market share?
5. How do Paragraph IV settlements usually alter generic launch timing for branded diabetology products?

---

References

1. APA style placeholder: No cited sources were provided in the prompt, and no in-text source citations were generated.

DrugChatter Q&A for JARDIANCE

When did jardiance go generic?
Patent for jardiance in heart failure?
Jardiance 10 mg price in china?
When does jardiance patent expire?
Jardiance expiry by country?